Bristol Myers Squibb (BMY) EBIT (2009 - 2026)
Bristol Myers Squibb (BMY) reported EBIT of -$182.0 million for Q1 2026, down 193.55% year-over-year from $194.6 million in Q1 2025, and up 93.07% quarter-over-quarter from -$2.6 billion in Q4 2025.
Bristol Myers Squibb (BMY) EBIT (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has 18 years of EBIT data on file, last reported at -$182.0 million in Q1 2026.
- EBIT for Q1 2026 came in at -$182.0 million, down 193.55% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.7 billion (up 40.6% YoY), and the FY2025 annual result was -$4.6 billion, up 79.38% from the prior year.
- EBIT grew to -$182.0 million in Q1 2026 per BMY's latest filing, from -$2.6 billion in the prior quarter.
- Over five years, EBIT peaked at $204.0 million in Q1 2023 and troughed at -$14.4 billion in Q1 2024.
- A 5-year average of -$1.9 billion and a median of -$784.0 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2023 and 2024: EBIT surged 126.02% in 2023, then tumbled 7182.35% in 2024.
- A 5-year view of EBIT shows it stood at -$734.0 million in 2022, then slumped by 45.91% to -$1.1 billion in 2023, then sank by 332.96% to -$4.6 billion in 2024, then surged by 43.35% to -$2.6 billion in 2025, then jumped by 93.07% to -$182.0 million in 2026.
- Business Quant data shows BMY's EBIT at -$182.0 million in Q1 2026, -$2.6 billion in Q4 2025, and -$321.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 3.09 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 9.50 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 6.36 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 3.99 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -182.00 Mn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -182.00 Mn |
| Dec 31, 2025 | -2.63 Bn |
| Sep 30, 2025 | -321.00 Mn |
| Jun 30, 2025 | -1.60 Bn |
| Mar 31, 2025 | -62.00 Mn |
| Dec 31, 2024 | -4.64 Bn |
| Sep 30, 2024 | -1.28 Bn |
| Jun 30, 2024 | -1.98 Bn |
| Mar 31, 2024 | -14.45 Bn |
| Dec 31, 2023 | -1.07 Bn |
| Sep 30, 2023 | -369.00 Mn |
| Jun 30, 2023 | -1.02 Bn |
| Mar 31, 2023 | 204.00 Mn |
| Dec 31, 2022 | -734.00 Mn |
| Sep 30, 2022 | -144.00 Mn |
| Jun 30, 2022 | -762.00 Mn |
| Mar 31, 2022 | -784.00 Mn |
| Dec 31, 2021 | -498.00 Mn |
| Sep 30, 2021 | -134.00 Mn |
| Jun 30, 2021 | -899.00 Mn |